Human Liver miRNA Search Results


mirna pcr array human liver mifinder miscript mirna pcr array mihs-3116zg  (Qiagen)
90
Qiagen mirna pcr array human liver mifinder miscript mirna pcr array mihs-3116zg
Association between circulating <t>miRNA</t> levels and severity of hepatic fibrosis and HCC in CHC. ( A ) miRNA-122-5p, ( C ) miRNA-151a-5p, and ( D ) miRNA-142-3p show a decreased expression in HCC, compared to cirrhosis, whereas ( B ) miRNA-486-5p shows an increased expression in HCC, compared to cirrhosis. ( E ) miRNA-409-3p shows an increased expression in F4, when compared to mild disease. ( F ) miRNA-19b-3p shows an increased expression in HCC compared to mild disease. Lines represent mean expression levels (±SEM). * p < 0.05, ** p < 0.01, *** p < 0.001. (Abbreviations: CHC = chronic Hepatitis C; F0-2 = mild disease; F4 = cirrhosis; HCC = hepatocellular carcinoma; miRNA = microRNA; SEM = standard error of the mean).
Mirna Pcr Array Human Liver Mifinder Miscript Mirna Pcr Array Mihs 3116zg, supplied by Qiagen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mirna pcr array human liver mifinder miscript mirna pcr array mihs-3116zg/product/Qiagen
Average 90 stars, based on 1 article reviews
mirna pcr array human liver mifinder miscript mirna pcr array mihs-3116zg - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
liver-specific mirna array qiagen liver pcr-array human liver mifinder  (Qiagen)
90
Qiagen liver-specific mirna array qiagen liver pcr-array human liver mifinder
Association between circulating <t>miRNA</t> levels and severity of hepatic fibrosis and HCC in CHC. ( A ) miRNA-122-5p, ( C ) miRNA-151a-5p, and ( D ) miRNA-142-3p show a decreased expression in HCC, compared to cirrhosis, whereas ( B ) miRNA-486-5p shows an increased expression in HCC, compared to cirrhosis. ( E ) miRNA-409-3p shows an increased expression in F4, when compared to mild disease. ( F ) miRNA-19b-3p shows an increased expression in HCC compared to mild disease. Lines represent mean expression levels (±SEM). * p < 0.05, ** p < 0.01, *** p < 0.001. (Abbreviations: CHC = chronic Hepatitis C; F0-2 = mild disease; F4 = cirrhosis; HCC = hepatocellular carcinoma; miRNA = microRNA; SEM = standard error of the mean).
Liver Specific Mirna Array Qiagen Liver Pcr Array Human Liver Mifinder, supplied by Qiagen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/liver-specific mirna array qiagen liver pcr-array human liver mifinder/product/Qiagen
Average 90 stars, based on 1 article reviews
liver-specific mirna array qiagen liver pcr-array human liver mifinder - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


Association between circulating miRNA levels and severity of hepatic fibrosis and HCC in CHC. ( A ) miRNA-122-5p, ( C ) miRNA-151a-5p, and ( D ) miRNA-142-3p show a decreased expression in HCC, compared to cirrhosis, whereas ( B ) miRNA-486-5p shows an increased expression in HCC, compared to cirrhosis. ( E ) miRNA-409-3p shows an increased expression in F4, when compared to mild disease. ( F ) miRNA-19b-3p shows an increased expression in HCC compared to mild disease. Lines represent mean expression levels (±SEM). * p < 0.05, ** p < 0.01, *** p < 0.001. (Abbreviations: CHC = chronic Hepatitis C; F0-2 = mild disease; F4 = cirrhosis; HCC = hepatocellular carcinoma; miRNA = microRNA; SEM = standard error of the mean).

Journal: International Journal of Molecular Sciences

Article Title: Serum MicroRNAs as Biomarkers in Hepatitis C: Preliminary Evidence of a MicroRNA Panel for the Diagnosis of Hepatocellular Carcinoma

doi: 10.3390/ijms20040864

Figure Lengend Snippet: Association between circulating miRNA levels and severity of hepatic fibrosis and HCC in CHC. ( A ) miRNA-122-5p, ( C ) miRNA-151a-5p, and ( D ) miRNA-142-3p show a decreased expression in HCC, compared to cirrhosis, whereas ( B ) miRNA-486-5p shows an increased expression in HCC, compared to cirrhosis. ( E ) miRNA-409-3p shows an increased expression in F4, when compared to mild disease. ( F ) miRNA-19b-3p shows an increased expression in HCC compared to mild disease. Lines represent mean expression levels (±SEM). * p < 0.05, ** p < 0.01, *** p < 0.001. (Abbreviations: CHC = chronic Hepatitis C; F0-2 = mild disease; F4 = cirrhosis; HCC = hepatocellular carcinoma; miRNA = microRNA; SEM = standard error of the mean).

Article Snippet: During the screening phase, a miRNA PCR Array (Human Liver miFinder miScript miRNA PCR Array MIHS-3116ZG; Qiagen) was used to simultaneously measure the expression of 372 liver-related miRNAs in all 60 samples.

Techniques: Expressing

Associations of circulating miRNA expression with the severity of disease in chronic Hepatitis C: Validation of selected miRNA expression levels using qRT-PCR.

Journal: International Journal of Molecular Sciences

Article Title: Serum MicroRNAs as Biomarkers in Hepatitis C: Preliminary Evidence of a MicroRNA Panel for the Diagnosis of Hepatocellular Carcinoma

doi: 10.3390/ijms20040864

Figure Lengend Snippet: Associations of circulating miRNA expression with the severity of disease in chronic Hepatitis C: Validation of selected miRNA expression levels using qRT-PCR.

Article Snippet: During the screening phase, a miRNA PCR Array (Human Liver miFinder miScript miRNA PCR Array MIHS-3116ZG; Qiagen) was used to simultaneously measure the expression of 372 liver-related miRNAs in all 60 samples.

Techniques: Expressing, Biomarker Discovery

ROC curves for individual serum miRNAs to identify cirrhosis or HCC in chronic hepatitis C ( A ). ROC curve performance of miRNA-122-5p with AUC of 0.69 (95% CI 0.51–0.86, p = 0.023) and miRNA-409-3p with AUC of 0.74 (95% CI 0.58–0.90, p = 0.004) to identify cirrhosis when compared to mild disease. ( B ) ROC curve performance of selected miRNAs to identify HCC when compared to cirrhosis as follows: miRNA-486-5p, AUC of 0.78 (95% CI 0.63–0.93, p < 0.001); miRNA-151a-5p, AUC of 0.70 (95% CI 0.54–0.87, p = 0.014); miRNA-122-5p, AUC of 0.85 (95% CI 0.72–0.97, p < 0.001); miRNA-142-3p, AUC of 0.60 (95% CI 0.42–0.78, p = 0.140). (Abbreviations: AUC = area under the curve; HCC = hepatocellular carcinoma; miRNA = microRNA; ROC = receiver operating characteristic; 95% CI = 95% confidence interval).

Journal: International Journal of Molecular Sciences

Article Title: Serum MicroRNAs as Biomarkers in Hepatitis C: Preliminary Evidence of a MicroRNA Panel for the Diagnosis of Hepatocellular Carcinoma

doi: 10.3390/ijms20040864

Figure Lengend Snippet: ROC curves for individual serum miRNAs to identify cirrhosis or HCC in chronic hepatitis C ( A ). ROC curve performance of miRNA-122-5p with AUC of 0.69 (95% CI 0.51–0.86, p = 0.023) and miRNA-409-3p with AUC of 0.74 (95% CI 0.58–0.90, p = 0.004) to identify cirrhosis when compared to mild disease. ( B ) ROC curve performance of selected miRNAs to identify HCC when compared to cirrhosis as follows: miRNA-486-5p, AUC of 0.78 (95% CI 0.63–0.93, p < 0.001); miRNA-151a-5p, AUC of 0.70 (95% CI 0.54–0.87, p = 0.014); miRNA-122-5p, AUC of 0.85 (95% CI 0.72–0.97, p < 0.001); miRNA-142-3p, AUC of 0.60 (95% CI 0.42–0.78, p = 0.140). (Abbreviations: AUC = area under the curve; HCC = hepatocellular carcinoma; miRNA = microRNA; ROC = receiver operating characteristic; 95% CI = 95% confidence interval).

Article Snippet: During the screening phase, a miRNA PCR Array (Human Liver miFinder miScript miRNA PCR Array MIHS-3116ZG; Qiagen) was used to simultaneously measure the expression of 372 liver-related miRNAs in all 60 samples.

Techniques:

ROC curve of serum miRNA panels to identify cirrhosis or HCC in chronic Hepatitis C ( A ) miRNA panel (miRNA-122-5p and miRNA-409-3p) performance to identify cirrhosis, compared to mild disease, with AUC of 0.80 (95% CI 0.66–0.95, p < 0.001). ( B ) miRNA panel to identify HCC, compared to cirrhosis, using miRNA-122-5p, miRNA-486-5p, and miRNA-142-3p with AUC of 0.94 (95% CI 0.87–1.00, p < 0.001). (Abbreviations: AUC = area under the curve; F0-2 = mild disease; F4 = cirrhosis; HCC = hepatocellular carcinoma; miRNA = microRNA; ROC = receiver operating characteristic; 95% CI = 95% confidence interval).

Journal: International Journal of Molecular Sciences

Article Title: Serum MicroRNAs as Biomarkers in Hepatitis C: Preliminary Evidence of a MicroRNA Panel for the Diagnosis of Hepatocellular Carcinoma

doi: 10.3390/ijms20040864

Figure Lengend Snippet: ROC curve of serum miRNA panels to identify cirrhosis or HCC in chronic Hepatitis C ( A ) miRNA panel (miRNA-122-5p and miRNA-409-3p) performance to identify cirrhosis, compared to mild disease, with AUC of 0.80 (95% CI 0.66–0.95, p < 0.001). ( B ) miRNA panel to identify HCC, compared to cirrhosis, using miRNA-122-5p, miRNA-486-5p, and miRNA-142-3p with AUC of 0.94 (95% CI 0.87–1.00, p < 0.001). (Abbreviations: AUC = area under the curve; F0-2 = mild disease; F4 = cirrhosis; HCC = hepatocellular carcinoma; miRNA = microRNA; ROC = receiver operating characteristic; 95% CI = 95% confidence interval).

Article Snippet: During the screening phase, a miRNA PCR Array (Human Liver miFinder miScript miRNA PCR Array MIHS-3116ZG; Qiagen) was used to simultaneously measure the expression of 372 liver-related miRNAs in all 60 samples.

Techniques:

K-fold (5-fold) cross validation ROC curve of serum miRNA panels to identify cirrhosis or HCC in chronic Hepatitis C ( A ) miRNA panel (miRNA-122-5p and miRNA-409-3p) 5-fold cross validation performance to identify cirrhosis, compared to mild disease, demonstrates an AUC of 0.79 (95% CI 0.65–0.93). ( B ) miRNA panel to identify HCC, compared to cirrhosis, using miRNA-122-5p, miRNA-486-5p, and miRNA-142-3p, demonstrates an AUC of 0.91 (95% CI 0.81–1.0). (Abbreviations: AUC = area under the curve; F0-2 = mild disease; F4 = cirrhosis; HCC = hepatocellular carcinoma; miRNA = microRNA; ROC = receiver operating characteristic; 95% CI = 95% confidence interval).

Journal: International Journal of Molecular Sciences

Article Title: Serum MicroRNAs as Biomarkers in Hepatitis C: Preliminary Evidence of a MicroRNA Panel for the Diagnosis of Hepatocellular Carcinoma

doi: 10.3390/ijms20040864

Figure Lengend Snippet: K-fold (5-fold) cross validation ROC curve of serum miRNA panels to identify cirrhosis or HCC in chronic Hepatitis C ( A ) miRNA panel (miRNA-122-5p and miRNA-409-3p) 5-fold cross validation performance to identify cirrhosis, compared to mild disease, demonstrates an AUC of 0.79 (95% CI 0.65–0.93). ( B ) miRNA panel to identify HCC, compared to cirrhosis, using miRNA-122-5p, miRNA-486-5p, and miRNA-142-3p, demonstrates an AUC of 0.91 (95% CI 0.81–1.0). (Abbreviations: AUC = area under the curve; F0-2 = mild disease; F4 = cirrhosis; HCC = hepatocellular carcinoma; miRNA = microRNA; ROC = receiver operating characteristic; 95% CI = 95% confidence interval).

Article Snippet: During the screening phase, a miRNA PCR Array (Human Liver miFinder miScript miRNA PCR Array MIHS-3116ZG; Qiagen) was used to simultaneously measure the expression of 372 liver-related miRNAs in all 60 samples.

Techniques: Biomarker Discovery

ROC curves to identify cirrhosis or HCC using FIB-4 or APRI alone, or in combination with circulating miRNA panels in chronic Hepatitis C. ( A ) In distinguishing cirrhosis, the performance of FIB-4 (AUC = 0.87, 95% CI 0.75–0.98, p < 0.001; using a cut-off of >1.45 to exclude advanced fibrosis) was enhanced in combination with the cirrhosis miRNA panel described in A (AUC = 0.89, 95% CI 0.79–0.99, p < 0.001); ( B ) in distinguishing cirrhosis, the performance of APRI (AUC = 0.84, 95% CI 0.71–0.97, p < 0.001; using a cut-off of >1.0 to exclude cirrhosis) was enhanced in combination with the cirrhosis miRNA panel described in A (AUC =0.87, 95% CI 0.76–0.98, p < 0.001); ( C ) AFP alone demonstrated poor diagnostic utility in the detection of HCC (AUC = 0.64, 95% CI 0.47–0.82, p = 0.065; using a cut-off of >20 to diagnose HCC) and when used in combination with the HCC miRNA panel described in B there was no improvement in the HCC miRNA panel’s ability to detect HCC (AUC = 0.94, 95% CI 0.88–1.00, p < 0.001). (Abbreviations: APRI = aspartate aminotransferase to platelet ratio; AFP = alpha-fetoprotein; AUC = area under the curve; FIB-4 = Fibrosis-4 biomarker panel; HCC = hepatocellular carcinoma; miRNA = microRNA; ROC = receiver operating characteristic; 95% CI = 95% confidence interval).

Journal: International Journal of Molecular Sciences

Article Title: Serum MicroRNAs as Biomarkers in Hepatitis C: Preliminary Evidence of a MicroRNA Panel for the Diagnosis of Hepatocellular Carcinoma

doi: 10.3390/ijms20040864

Figure Lengend Snippet: ROC curves to identify cirrhosis or HCC using FIB-4 or APRI alone, or in combination with circulating miRNA panels in chronic Hepatitis C. ( A ) In distinguishing cirrhosis, the performance of FIB-4 (AUC = 0.87, 95% CI 0.75–0.98, p < 0.001; using a cut-off of >1.45 to exclude advanced fibrosis) was enhanced in combination with the cirrhosis miRNA panel described in A (AUC = 0.89, 95% CI 0.79–0.99, p < 0.001); ( B ) in distinguishing cirrhosis, the performance of APRI (AUC = 0.84, 95% CI 0.71–0.97, p < 0.001; using a cut-off of >1.0 to exclude cirrhosis) was enhanced in combination with the cirrhosis miRNA panel described in A (AUC =0.87, 95% CI 0.76–0.98, p < 0.001); ( C ) AFP alone demonstrated poor diagnostic utility in the detection of HCC (AUC = 0.64, 95% CI 0.47–0.82, p = 0.065; using a cut-off of >20 to diagnose HCC) and when used in combination with the HCC miRNA panel described in B there was no improvement in the HCC miRNA panel’s ability to detect HCC (AUC = 0.94, 95% CI 0.88–1.00, p < 0.001). (Abbreviations: APRI = aspartate aminotransferase to platelet ratio; AFP = alpha-fetoprotein; AUC = area under the curve; FIB-4 = Fibrosis-4 biomarker panel; HCC = hepatocellular carcinoma; miRNA = microRNA; ROC = receiver operating characteristic; 95% CI = 95% confidence interval).

Article Snippet: During the screening phase, a miRNA PCR Array (Human Liver miFinder miScript miRNA PCR Array MIHS-3116ZG; Qiagen) was used to simultaneously measure the expression of 372 liver-related miRNAs in all 60 samples.

Techniques: Diagnostic Assay, Biomarker Discovery